Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 18/20 | 0.39 |
| ▸ | MMP2 | P08253 | 5/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835144 | 0.84 | ADAMTS5 (0.54) | ADAMTS5MMP2MMP13MMP14ADAM17 | |
| SCHEMBL29835174 | 0.84 | ADAMTS5 (0.54) | ADAMTS5MMP2MMP13MMP14ADAM17 | |
| SCHEMBL29250239 | 0.84 | ADAMTS5 (0.54) | ADAMTS5MMP2MMP13MMP14ADAM17 | |
| SCHEMBL23745336 | 0.84 | ADAMTS5 (0.54) | ADAMTS5MMP2MMP13MMP14ADAM17 | |
| SCHEMBL29250240 | 0.84 | ADAMTS5 (0.54) | ADAMTS5MMP2MMP13MMP14ADAM17 | |
| SCHEMBL29835131 | 0.84 | ADAMTS5 (0.54) | ADAMTS5MMP2MMP13MMP14ADAM17 | |
| SCHEMBL23745335 | 0.84 | ADAMTS5 (0.54) | ADAMTS5MMP2MMP13MMP14ADAM17 | |
| SCHEMBL23745213 | 0.84 | ADAMTS5 (0.54) | ADAMTS5MMP2MMP13MMP14ADAM17 | |
| SCHEMBL23745423 | 0.83 | ADAMTS5 (0.44) | ADAMTS5MMP2MMP13MMP14ADAM17 | |
| SCHEMBL23745378 | 0.80 | ADAMTS5 (0.46) | ADAMTS5MMP2MMP13MMP14ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021158626-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. (US) | 2021-08-12 | — | — | WO | disclosed |